trending Market Intelligence /marketintelligence/en/news-insights/trending/HjUZG9jye3-Mh1IUBei4SA2 content esgSubNav
In This List

Pfizer's investigational treatment shows anti-tumor activity in study

Blog

Gauging Supply Chain Risk In Volatile Times

Blog

Insight Weekly: Banks' efficiency push; vacuuming carbon; Big Pharma diversity goals

Blog

The Future of Risk Management Digitization in Credit Risk Management

Blog

Climate Credit Analytics: Diving into the model


Pfizer's investigational treatment shows anti-tumor activity in study

Pfizer Inc.'s investigational drug talazoparib showed anti-tumor activity in patients with germline or inherited BRCA1/2-positive advanced breast cancer in a phase 2 trial.

The study investigated the clinical efficacy and safety of talazoparib in 83 heavily pretreated gBRCA+ advanced breast cancer patients, with objective response rate, or ORR, by independent radiology review as the primary endpoint.

A 21% ORR was observed in a group of 49 patients who previously responded to platinum-based chemotherapy and developed disease progression, while a 37% ORR was logged in a group of 35 patients who developed disease progression following at least three lines of non-platinum-based therapy, Pfizer said in a news release.

Talazoparib is also being investigated in a fully enrolled phase 3 trial in advanced gBRCA+ breast cancer.

BRCA1 and BRCA2 are human genes producing proteins for DNA repair. An alteration or mutation of either of the genes could result in a stunted progression of DNA repair, resulting in certain types of cancer.